What is BrightPath Biotherapeutics Co Days Payable?
BrightPath Biotherapeutics CoTSE:4594 +2.04%46 Days Payable is 170.06 as of Mar. 2026, which is 14% below its 10-year median of 197.81. GuruFocus rates TSE:4594 with a GF Score™ of 46/100 and a GF Value™ of 円4.64 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 701 Biotechnology companies, BrightPath Biotherapeutics Co ranks better than 71.18% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4594 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BrightPath Biotherapeutics Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Days Payable distribution charts can be found below:
* The bar in red indicates where BrightPath Biotherapeutics Co's Days Payable falls into.
BrightPath Biotherapeutics Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrightPath Biotherapeutics Co (TSE:4594) has a Days Payable of 170.06 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BrightPath Biotherapeutics Co and its competitors. This is 14% below median its historical median of 197.81. Over the past decade, BrightPath Biotherapeutics Co's Days Payable has ranged from 18.14 to 1,190.54. According to the industry distribution chart, BrightPath Biotherapeutics Co ranks #202 out of 701 companies in the Biotechnology industry, placing it in the top 28.8%.
Is BrightPath Biotherapeutics Co's Days Payable too high?
BrightPath Biotherapeutics Co's current Days Payable of 170.06 is 14% below median its 10-year median of 197.81. Over the past 10 years, this metric has ranged from a low of 18.14 to a high of 1,190.54. The Biotechnology industry median Days Payable is 112.84. BrightPath Biotherapeutics Co's value of 170.06 is 50.7% above this industry median. Based on the distribution chart, BrightPath Biotherapeutics Co ranks #202 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BrightPath Biotherapeutics Co ranks #202 out of 701 companies for Days Payable. This puts BrightPath Biotherapeutics Co in the upper half of its industry. The industry median Days Payable is 112.84. BrightPath Biotherapeutics Co's value of 170.06 is 50.7% above this benchmark. Historically, BrightPath Biotherapeutics Co's own Days Payable has ranged from 18.14 to 1,190.54 over the past decade. While the company's 10-year median is 197.81 vs. the industry median of 112.84, BrightPath Biotherapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BrightPath Biotherapeutics Co's current Days Payable of 170.06 is 50.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BrightPath Biotherapeutics Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BrightPath Biotherapeutics Co's current Days Payable is 170.06, which is 14% below median its own 10-year median of 197.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co (TSE:4594) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.64, compared to a current price of 円50.00 — trading 977.6% above its estimated fair value. The current Days Payable is 170.06, which is 14% below median its 10-year median of 197.81 and 50.7% above the Biotechnology industry median of 112.84. BrightPath Biotherapeutics Co's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current Days Payable is 170.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BrightPath Biotherapeutics Co (TSE:4594) Overvalued in 2026?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co stock appears to be overvalued.
The current stock price of 円50.00 is trading 977.6% above its estimated GF Value™ of 円4.64.
GuruFocus considers BrightPath Biotherapeutics Co to be Significantly Overvalued.
Key valuation signals for TSE:4594:
Days Payable: 170.06 (14% below median its 10-year median of 197.81)
GF Value™: 円4.64 vs. price of 円50.00 (977.6% above fair value)
Industry Position: 50.7% above the Biotechnology median (#202 of 701)
No single metric tells the full story. See the TSE:4594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BrightPath Biotherapeutics Co Business Description
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
46GF Score
Get the complete analysis for TSE:4594
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4594 has been successfully added to your 
